Entries by Gerry Shaw

December 2023 News

      We now have new data on two rabbit polyclonal antibodies to microtubule associated protein 2, RPCA-MAP2A/B and a new antibody RPCA-MAP2D. The MAP2 gene produces several different sized proteins by alternate transcription. MAP2C and MAP2D are lower molecular weight isotypes which are expressed early in development and are around 70kDa molecular size when run on […]

August 2023 News

      We release yet more novel antibodies. We made a novel rabbit polyclonal and a mouse mpnoclonal to the enzyme catalase, RPCA-Catalase and MCA-6H14, both good markers odf peroxisomes. We also raised rabbit polyclonal antibodies against human Sigma-1 receptor RPCA-Sigma-1r and human γ-synuclein, RPCA-SNCG. We document that all work well on western blots for IF, ICC […]

June 2023 News

We have now finished testing all our rabbit polyclonal antibodies for immunohistochemistry on formalin fixed and paraffin embedded (FFPE) rodent and rodent tissues. So we found that many of them work very well, as shown in the examples below. So now we can recommend (or not) all of our antibodies on FFPE human and rodent […]

April 2023 News

      Our recent work on the Uman NF-L antibodies published in pre-print form in BioRχiv was cited for the first time, in JAMA (the Journal of the American Medical Association), only the world’s highest impact medical journal! For a download see here. This work is now published in peer reviewed and freely downloadable form from the […]

March 2023 News

      The data in our recent publication in BioRχiv preprint, entitled “Uman Type NF-L Antibodies Are Effective Reagents for the Imaging of Neurodegeneration” was edited and modified to include further data and was submitted for peer review at the journal “Brain Communications“. It has now been accepted for publication with the same title except that “NF-L” […]

December 2022 News

      We release two new protein constructs, PROT-r-NF-L-Rct and PROT-r-NF-L-Stan. These constructs are designed to be used as protein standards for current neurofilament NF-L antibody based assays, such as the Uman/Quanterix NF-LIGHT™ and Quanterix Simoa™ assays. The two antibodies used in these assays both bind to the center of the “Coil II” region of α-helical “Rod” […]

September 2022 News

      Our recent progress with the characterization of NF-L antibodies allow us to generate a novel and useful new reagent. This is our NF-L biomarker assay standard PROT-r-NF-L-Stan. This is a small recombinant protein which includes the epitopes for the two antibodies used in the NF-LIGHT™ and Quanterix Simoa™ NF-L biomarker assays. The recombinant construct is […]

August 2022 News

      The Uman Diagnostics NF-LIGHT™ ELISA is a widely used ELISA type assay based on two mouse monoclonal antibodies to the neurofilament NF-L protein. One Uman antibody called variously UD1 or 2.1 is the detection reagent and the other, UD2, also known as 47.3, is the capture reagent (see Norgren et al. 2002). The same pair […]

Recombinant Human NF-L Rod 80-400

Human NF-L sequence was based on that was NP_006149.2 which was inserted into the eukaryotic expression vector pET30a(+) which adds an N terminal His-tag and some other sequence, underlined below. This sequence includes a thrombin cleavage site (blue), an S-tag affinity peptide (red) and an enterokinase cleavage site (green). This construct is designed to express […]

Recombinant Full Length Human NF-L

Human NF-L sequence was based on that was NP_006149.2 which was inserted into the eukaryotic expression vector pET30a(+) which adds an N terminal His-tag and some other sequence, underlined below. This sequence includes a thrombin cleavage site (blue), an S-tag affinity peptide (red) and an enterokinase cleavage site (green). MHHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS EFMSSFSYEP […]